Effect of resistance training on natural killer cell activity in women recovering from breast cancer treatment: A randomised controlled trial

Not Applicable

• Conditions: breast cancer; Cancer - Breast

• Registration Number: ACTRN12612000346875
• Lead Sponsor: Amanda McKee

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2012-03-26
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: ot yet recruiting
• Sex: Female
• Target Recruitment: 50

Inclusion Criteria

Histologically confirmed stage I to IIIA breast cancer with no evidence of recurrent disease; postmenopausal, age 40-70 years; diagnosed with breast cancer within the previous 2.5 years and completed surgery, radiotherapy and/or chemotherapy within the past 1.5 years, with or without current use of hormonal therapy (e.g. tamoxifen, aromatase inhibitors); sedentary (<30min of continuous moderate-intensity exercise, 3 times per week), absence of autoimmune systemic disease(s); with or without existing upper extremity lymphedema; stable underlying chronic diseases; ability to communicate in English; no acute or chronic medical conditions which would make resistance training potentially hazardous or primary outcomes impossible to assess; willingness and cognitive ability to provide written informed consent to participate in the trial.

Exclusion Criteria

failure to meet inclusion criteria

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
atural killer cell activity measured as percent lysis at multiple target to effector ratios. Blood will be collected twice at week 0 and twice at week 17 to establish a true resting norm (mean of the two collections) for this measure and the secondary immune and inflammatory markers. Blood will be taken by a certified phlebotomist. Blood will then be analysed in the University laboratory and commercial pathology laboratories.[Week 0 and Week 17]

Secondary Outcome Measures

Name	Time	Method
Muscular strength. Muscular strength will be assessed via isokinetic dynamometry on the kincom. Shoulder internal and external rotation and knee flexion and extension will be assessed. 3 trials will be implemented, with the highest measure recorded.[Week 0, Week 8, Week 17];Additional immune and inflammatory parameters: Full blood count, IL-6, lymphocyte proliferation, and lymphocyte subsets, CRP levels, blood lipids[Week 0 and Week 17];Quality of life: As assessed by the FACT-G (cancer general scale), FACIT-fatigue (cancer fatigue scale), and the SF-36 health questionnaire[Week 0 and Week 17]